Merck Stock Rises on Analyst Optimism and Strong Revenue
Merck & Co. (ISIN US58933Y1055) saw its stock rise 1.14% on October 6, 2026, reaching USD 141.12 on the NYSE. Analysts maintain a Moderate Buy consensus, with an average 1-year price target of USD 146.36, suggesting a 3.7% upside from the current price. The consensus is split between 16 Buy and 11 Hold ratings, indicating cautious optimism.
The stock's performance reflects a mixed outlook. It trades 10.1% below its 52-week high of USD 156.92 but remains 72.1% above its low of USD 82.01. With a market capitalization of USD 348.6 billion, Merck remains one of the largest publicly traded drugmakers.
Merck's second-quarter 2026 revenue hit USD 16.61 billion, surpassing estimates of USD 16.37 billion. This marks a 5.1% year-over-year increase. The company reported a quarterly EPS loss of USD 0.13, better than the expected USD 0.26 loss. Strong sales in oncology and animal health were highlighted as key drivers.
Looking ahead, Merck is scheduled to host its third-quarter 2026 earnings call on October 29, 2026, and an investor event at ESMO 2026 on October 26, 2026. These events will provide further insights into the company's performance and strategic direction.